Marc S. Ernstoff

Marc S. Ernstoff's AcademicInfluence.com Rankings

Marc S. Ernstoff

Philosophy

#4546

World Rank

#7107

Historical Rank

Logic

#1973

World Rank

#2859

Historical Rank

philosophy Degrees

Marc S. Ernstoff

Biology

#5966

World Rank

#8575

Historical Rank

Immunology

#300

World Rank

#311

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Marc S. Ernstoff Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Marc S. Ernstoff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. (2015) (2383)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. (2018) (2082)
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 (2023) (2027)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017) (1274)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. (2012) (963)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. (2001) (880)
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. (2000) (856)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain (2018) (803)
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. (2009) (731)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. (2016) (730)
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. (1999) (729)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. (2005) (632)
A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma (2004) (511)
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. (2013) (462)
Management of Immunotherapy-Related Toxicities, Version 1.2019. (2019) (363)
VISTA is an immune checkpoint molecule for human T cells. (2014) (330)
Homozygous deletions within human chromosome band 9p21 in melanoma. (1992) (323)
Interferons in the treatment of human cancer. (1984) (322)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021) (280)
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. (2000) (269)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). (2014) (253)
Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls (2009) (250)
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America (2010) (249)
COVID-19 and Cancer: a Comprehensive Review (2020) (222)
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. (2020) (217)
Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. (1997) (206)
Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) (2008) (203)
Expressive Disclosure and Health Outcomes in a Prostate Cancer Population (2002) (185)
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma (2013) (174)
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2014) (171)
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. (1985) (170)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events (2021) (168)
Melanoma, version 2.2016 clinical practice guidelines in oncology (2016) (161)
Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy (2011) (160)
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. (1985) (151)
Tracking antigen‐driven responses by flow cytometry: Monitoring proliferation by dye dilution (2008) (151)
Tissue-shrinkage correction factor in the calculation of prostate cancer volume. (1996) (146)
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group (2002) (143)
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study (2018) (141)
A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. (1999) (138)
Systemic Therapy for Melanoma: ASCO Guideline. (2020) (137)
The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma (2014) (127)
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. (2019) (123)
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. (2002) (122)
Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment (2018) (121)
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. (2011) (116)
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. (2017) (115)
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors (2018) (114)
Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide (1999) (112)
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. (2011) (110)
A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes (2009) (107)
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. (2008) (101)
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden (2018) (99)
Multiple primary melanoma: two-year results from a population-based study. (2006) (97)
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. (2008) (90)
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy. (2020) (90)
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (89)
Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-α2a Therapy in Metastatic Renal Cell Carcinoma Patients (2009) (88)
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
A Randomized Trial of Ex vivo CD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival (2010) (85)
Immunotherapy for the Treatment of Glioblastoma (2012) (84)
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. (2002) (84)
An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer (2014) (84)
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma (2008) (84)
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. (2007) (80)
Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850) (2006) (79)
Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. (2018) (79)
Purity and yield of melanoma exosomes are dependent on isolation method (2019) (76)
Pigmentary characteristics and moles in relation to melanoma risk (2005) (75)
Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2015) (75)
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors (2011) (74)
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. (2011) (74)
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy (2020) (72)
Clinical EPR: unique opportunities and some challenges. (2014) (71)
In vivo description of dendritic cells in human renal cell carcinoma. (1999) (71)
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced an (2015) (70)
Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. (2014) (69)
A phase II study of gemcitabine and capecitabine in metastatic renal cancer (2006) (62)
Melanoma: therapeutic options with recombinant interferons. (1985) (62)
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up (1995) (62)
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival (2018) (61)
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). (2019) (60)
A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. (2000) (59)
E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. (2010) (59)
Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. (1986) (59)
Dysplastic nevi in association with multiple primary melanoma. (1988) (58)
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature (2019) (58)
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. (2021) (57)
Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. (2001) (56)
BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma (2014) (56)
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? (2008) (56)
Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell–Mediated Inflammation and Immunosuppression (2019) (56)
Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. (1984) (55)
Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder. (1991) (55)
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 (2018) (55)
Multiple murine BRafV600E melanoma cell lines with sensitivity to PLX4032 (2014) (55)
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy (2020) (55)
Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. (1998) (53)
Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. (2001) (52)
A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. (1987) (52)
Clinical electron paramagnetic resonance (EPR) oximetry using India ink. (2010) (51)
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients (2019) (51)
A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. (1990) (50)
Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. (1987) (50)
Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Clinicopathologic experience in a 100-bed hospital. (1987) (49)
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204) (2021) (48)
An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. (1992) (48)
A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC) (2007) (48)
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. (1993) (48)
Interferon α-2a and dacarbazine in melanoma (1990) (48)
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors (2021) (48)
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC) (2007) (47)
Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. (1995) (47)
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study (2020) (46)
Exposure to sunlamps, tanning beds, and melanoma risk (2008) (45)
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. (2018) (44)
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline (2021) (44)
Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program (2010) (43)
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study (2014) (43)
Multiparameter precursor analysis of T-cell responses to antigen. (2003) (42)
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. (2009) (41)
The effects of a high‐fat meal on single‐dose vemurafenib pharmacokinetics (2014) (41)
Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer (2007) (40)
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference (2007) (39)
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. (2018) (39)
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy (2021) (39)
Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. (2015) (38)
Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. (2015) (38)
Diagnosis of the dysplastic nevus in different populations. (1986) (38)
Phase I Pilot Trial of the Bispecific Antibody MDXH210 (anti-Fc&ggr;RI X anti–HER-2/neu) in Patients Whose Prostate Cancer Overexpresses HER-2/neu (2001) (38)
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity (2020) (37)
Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions. Studies of melanocytic nevi V. (1992) (37)
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets (2020) (37)
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. (2007) (36)
A Review of Exosomes and their Role in The Tumor Microenvironment and Host–Tumor “Macroenvironment” (2019) (36)
Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. (1994) (33)
Interferon alfa-2a for melanoma metastases (2002) (32)
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma (2016) (32)
Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. (2001) (32)
T-Cell Receptor ζ-Chain Expression on Tumor-infiltrating Lymphocytes from Renal Cell Carcinoma (1997) (31)
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). (1987) (31)
Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. (2002) (31)
Role of Interferons in the Thearpy of Melanoma (1990) (31)
Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival. (2016) (30)
Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States) (2002) (30)
Candida epiglottitis in an adult with acute nonlymphocytic leukemia. (1987) (30)
Modulation of antitumor immune responses by hematopoietic cytokines (2003) (29)
Interferon-induced reversible acute renal failure with nephrotic syndrome. (1992) (29)
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM (2016) (29)
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. (2011) (29)
Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang (2007) (29)
Recent skin self‐examination and doctor visits in relation to melanoma risk and tumour depth (2013) (29)
Primary melanoma of the spinal cord: a case report, molecular footprint, and review of the literature. (2011) (27)
Managing Metastatic Melanoma in 2022: A Clinical Review. (2022) (27)
Subcellular localization of metallothionein IIA in human bladder tumor cells using a novel epitope-specific antiserum. (1994) (26)
Immunophenotypic markers in renal cell carcinoma. (1990) (26)
Depressed Ability of Patients with Melanoma or Renal Cell Carcinoma to Generate Adherent Lymphokine-Activated Killer Cells (1991) (26)
Comparison of nonfamilial and familial melanoma. (1992) (26)
A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study (2013) (26)
Sonographic characteristics of epidermoidcyst of testicle (1990) (26)
Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies (2015) (26)
Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients (2016) (26)
Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. (1992) (25)
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. (2006) (25)
Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials. (1983) (25)
Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. (1995) (24)
Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo. (2001) (24)
1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (23)
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study (2021) (23)
Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). (2016) (23)
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma (2018) (23)
A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. (1991) (21)
Regulatory T-Cells and Associated Pathways in Metastatic Renal Cell Carcinoma (mRCC) Patients Undergoing DC-Vaccination and Cytokine-Therapy (2012) (21)
The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells (2016) (21)
In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. (1990) (21)
Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. (2004) (21)
Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma. (1985) (20)
Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma: Cancer and Leukemia Group B 509901 (2006) (20)
Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies (2020) (20)
Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient. (2016) (20)
Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials. (1983) (20)
Tumor‐related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte‐colony stimulating factor (GM‐CSF) (2006) (20)
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma (2017) (19)
Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor. (2017) (19)
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma (2019) (19)
1050OPHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (18)
Program to support safe administration of oral chemotherapy. (2006) (18)
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. (1990) (18)
Usefulness of frequent skin examination for the early detection of second primary cutaneous melanoma. (1989) (18)
A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC). (2013) (18)
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States (2021) (17)
Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890) (2003) (17)
A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008. (2004) (17)
Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis (2021) (17)
Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell Carcinoma Patients Treated with IL-2, Interferon-α and Dendritic Cell Vaccine (2012) (17)
The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer (2002) (17)
Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor (2017) (17)
Melanoma. Screening and education. (2000) (16)
Merkel cell polyomavirus and extrapulmonary small cell carcinoma (2013) (16)
NKG2D Ligand–Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors (2017) (16)
Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. (2006) (16)
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma (2018) (16)
Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma. (2013) (16)
DNA analysis of multiple synchronous renal cell carcinomas (1990) (15)
Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors. (2020) (15)
A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS). (2010) (15)
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing (2019) (15)
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. (2010) (15)
The pathogenesis of disseminated intravascular coagulation in sepsis. (1994) (15)
Reproducibility and validity in the clinical diagnosis of the nonfamilial dysplastic nevus: work in progress. (1986) (15)
Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics (2018) (14)
An Immunosuppressive Effect of Melanoma-derived Exosomes on NY-ESO-1 Antigen-specific Human CD8+ T Cells is Dependent on IL-10 and Independent of BRAFV600E Mutation in Melanoma Cell Lines (2020) (14)
T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. (1997) (14)
Been there, not done that--melanoma in the age of molecular therapy. (2011) (14)
In vitro Generation and in vivo Effects of Adherent Lymphokine-Activated Killer Cells and IL2 in Patients with Solid Tumors1 (1990) (13)
Testicular and penile cancer (1998) (13)
The natural killer–activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells (2014) (13)
A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. (2016) (13)
Quantitative DNA analysis of small renal cortical neoplasms. (1991) (12)
Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL) (2016) (12)
A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma (2005) (12)
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) (2019) (12)
Analysis of granulocyte-macrophage progenitor cells in patients treated with recombinant interferon alpha-2. (1985) (12)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
Oncologist uptake of comprehensive genomic profile guided targeted therapy (2019) (12)
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma (2013) (12)
Sonographic characteristics of epidermoid cyst of testicle. (1990) (11)
Vaccine-based immunotherapy for glioblastoma. (2013) (11)
Evaluation of the Combination of Vinblastine and Quinidine in Patients with Metastatic Renal Cell Carcinoma: A Phase I Study (1995) (11)
Challenges faced when identifying patients for combination immunotherapy. (2017) (11)
Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results. (2009) (10)
Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). (2011) (10)
Therapeutic vaccines in renal cell carcinoma. (2011) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma (2019) (10)
Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies. (2013) (10)
Co-Isolation of Cytokines and Exosomes: Implications for Immunomodulation Studies (2021) (10)
mTOR Pathway and mTOR Inhibitors in Cancer Therapy (2011) (10)
Dysplastic nevi in relation to superficial spreading melanoma. (1993) (9)
NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma (2018) (9)
Self-recognition and tumor response to immunotherapy. (2005) (9)
Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment. (1984) (9)
Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI. (1991) (9)
Biologic Response Modulation by Tumor Necrosis Factor Alpha (TNFα) in a Phase Ib Trial in Cancer Patients (1997) (9)
Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-α2b in locally/regionally advanced melanoma. (2018) (9)
Granulocytopenia in Cancer Patients Treated in a Phase I Trial with Recombinant Human Tumor Necrosis Factor (1991) (9)
5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study. (1996) (9)
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. (2013) (8)
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma (2021) (8)
Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals. (1989) (8)
Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients. (2005) (8)
Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma (2007) (7)
Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. (2022) (7)
Immunological assessment of melanoma patients treated with recombinant interferon gamma (r IFN γ, Biogen, Inc., Cambridge, MA) in a phase I/II trial (1985) (7)
Advances in the management of gastrointestinal malignancies. (1991) (7)
Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder (1990) (7)
Interferon alpha-2a and dacarbazine in melanoma. (1990) (7)
Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma (2019) (7)
Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. (2010) (7)
Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. (2010) (7)
The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes. (1992) (7)
Clinical Aspects of Prostate Cancer (2003) (6)
A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma (2004) (6)
Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (2017) (6)
Role of interferons in the therapy of melanoma. (1990) (6)
PHASE I TRIAL OF ALT-803, A NOVEL RECOMBINANT INTERLEUKIN-15 COMPLEX, IN PATIENTS WITH ADVANCED SOLID TUMORS (2018) (6)
Small and Isolated Immunohistochemistry-positive Cells in Melanoma Sentinel Lymph Nodes Are Associated With Disease-specific and Recurrence-free Survival Comparable to that of Sentinel Lymph Nodes Negative for Melanoma (2019) (6)
15 Adjuvant therapy of stage Iii and Iv malignant melanoma using yeast derived, Gm-csf (1997) (6)
Dye Dilution Proliferation Assay: Application of the DDPA to Identify Tumor-Specific T Cell Precursor Frequencies in Clinical Trials (2007) (6)
A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209–2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts) (2005) (6)
Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor. (1992) (6)
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372. (2018) (5)
Is pediatric melanoma always malignant? (2013) (5)
A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors. (2017) (5)
A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma. (2019) (5)
Phase 2 trial of talabostat in stage IV melanoma (2005) (5)
Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study (2007) (5)
Interferon alpha in combination with other biologics: the scientific rationale (1991) (5)
Intrapatient and Interpatient Comparison of Tumor Size and Monoclonal Antibody Uptake in Melanoma (1988) (5)
1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1) (2020) (5)
1039MO CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM) (2021) (5)
Indoleamine-2,3-dioxygenase enzyme expression and activity in polarized dendritic cells. (2009) (5)
A Rapid Exosome Isolation Using Ultrafiltration and Size Exclusion Chromatography (REIUS) Method for Exosome Isolation from Melanoma Cell Lines. (2021) (5)
Taxanes Synergize with the Bispecific Antibody MDXH447 to Enhance Antibody-Dependent Cell-Mediated Cytotoxicity (2003) (5)
Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield (1993) (5)
Therapeutic applications of cytokines for immunostimulation and immunosuppression: an update. (1996) (5)
ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors. (2021) (5)
Combination cytokine therapy in cancer. (1994) (4)
Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study (2022) (4)
Use and abuse of statistics in evidence-based medicine. (2002) (4)
Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone (2015) (4)
First-line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts) (2007) (4)
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours (2013) (4)
Publisher Correction: Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment (2019) (4)
Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2. (2021) (4)
A technique for catheterization and cystoscopic evaluation of cynomolgus monkey urinary bladders. (1988) (4)
A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors. (2018) (4)
A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain. (2015) (4)
Comparison of gallium-67 versus indium-111 monoclonal antibody (96.5, ZME-018) in detection of human melanoma in athymic mice. (1987) (4)
Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma. (2011) (4)
Algorithmic prediction of response to checkpoint inhibitors: Hyperprogressors versus responders. (2017) (4)
Systemic coagulation is activated in patients with meningioma and glioblastoma (2021) (4)
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study (2019) (4)
Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma. (2018) (4)
Mechanism of resistance to immune checkpoint inhibitors (2019) (3)
Toxicity comparison of neoadjuvant versus adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M‐VAC) in radical cystectomy patients (1990) (3)
Effect of intravenous recombinant alpha-2 interferon on monocyte Fc-dependent phagocytosis in patients with malignant melanoma. (1984) (3)
IMMUNOTHERAPY/BIOLOGICAL THERAPIES (2013) (3)
Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma (2021) (3)
The Critical Role of the NKG2D Receptor in CD8+CTL and CD8+CD56+ NKT Cell Cytotoxicity. (2004) (3)
Immunomodulatory effects of high‐dose and low‐dose interferon α2b in patients with high‐risk resected melanoma (2002) (3)
Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors. (2019) (3)
Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo (2013) (3)
A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors (2020) (3)
Phase I trial of dacarbazine and bortezomib in melanoma and soft tissue sarcoma. (2006) (3)
Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results. (2016) (3)
Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI). (2017) (3)
P2.04-26 Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC (2018) (2)
7109 Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure (2009) (2)
A clinical update: the role of interferon in the biotherapy of solid tumors. (1988) (2)
A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma. (2015) (2)
27 Adjuvant therapy of stage III and IV malignant melanoma using GM-CSF (1999) (2)
Phase I study of pembrolizumab in people with HIV and cancer. (2019) (2)
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (2)
INFLAMMATORY CELL INFILTRATE IN A RESPONDING METASTATIC NODULE AFTER ADOPTIVE TRANSFER OF IN VITRO SENSITIZED (IVS) T CELLS AND SYSTEMIC INTERLEUKIN-2 (1992) (2)
Toxicity of intravesical recombinant human tumor necrosis factor in cynomolgus monkeys. (1990) (2)
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy. (2019) (2)
Erratum to: Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma (2013) (2)
Immune Mobilization with Direct In-Vivo Effector Response: Clinical Trial with Favorable Implications for Post-Transplant Outcome. (2007) (2)
Assessment of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and treatment response in urothelial carcinoma (UC) patients (pts) undergoing surgery. (2017) (2)
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. (2007) (2)
Clinical and biochemical parameters as predictors of response to checkpoint inhibitors (CPI): A single institution experience. (2017) (2)
Erratum: A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens (Journal of Immunological Methods 230 (1999) (99-112) PII: S0022175999001362) (2000) (2)
Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study. (2018) (2)
Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy. (2011) (2)
Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors (2021) (2)
Analysis of Granulocyte-Macrophage Progenitor Cells in Patients Treated With Recombinant Interferon Alpha-2 (1985) (2)
Lymphodepletion with high-dose interleukin-2 (IL-2) and granulocyte macrophage-colony stimulating factor (GM-CSF) in metastatic melanoma patients: An interim analysis. (2006) (2)
Mitomycin C (MMC) combined with paclitaxel (PCTX)‐a clinical and pharmacokinetic study (1999) (2)
Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study. (2018) (2)
Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-Mediated Diarrhea and Colitis in Cancer Patients: A Multi-Center Study (2021) (1)
Comprehensive immune and mutational profile of melanoma. (2018) (1)
Microenvironment and Immunology VISTA Is an Immune Checkpoint Molecule for Human T Cells (2014) (1)
Erratum: Recent skin self-examination and doctor visits in relation to melanoma risk and tumor depth (British Journal of Dermatology (2012) 168 (571-576)) (2013) (1)
Abstract #724: A phase 1 clinical trial of immune response and safety of an active immunotherapy regimen co-targeting PRAME and PSMA antigens in subjects with advanced solid malignancies (2009) (1)
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) (2022) (1)
204 POSTER Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study (2008) (1)
DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors (2021) (1)
Factors associated with atypical moles in New Hampshire, USA. (2007) (1)
A Phase 2 Study of Talabostat in Patients With Stage IV Melanoma (2005) (1)
Molecular Basis for Treating Cutaneous Melanoma (2014) (1)
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2 (2020) (1)
Toxicity and antitumor effects of daily recombinant human interferonα2 (1982) (1)
Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer. (2001) (1)
9306 ORAL Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases (2011) (1)
Abstract 3413: Dissecting the combination of gemcitabine and the Chk1 inhibitor MK-8776in vitroandin vivo: cell cycle perturbation and the impact of administration schedule. (2013) (1)
Granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim) as adjuvant therapy of melanoma (2008) (1)
Adjuvant therapy of malignant melanoma using rhGM-CSF: 109 (1997) (1)
Publisher Correction: Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment (2019) (1)
Immunohistochemical phenotyping of malignant melanoma. A procedure whose time has come in pathology practice. (1990) (1)
Primary adrenocortical tumors: EGFR, c-Kit and Her-2/neu receptor staining patterns (2005) (1)
Correlation of lung cancer mutational profile with immune profile. (2018) (1)
Coumarin plus cimetidine: yet another angle for therapy of renal cell carcinoma. (1987) (1)
Cross-presentation of Tumor Antigens Is Increased by UVC Light Tumor Treatment Response (2009) (1)
Effect of CTLA-4 overexpression on response to ipilimumab in melanoma. (2018) (1)
A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma. (2012) (1)
NKG2D, An NK Cell Activating Receptor on CD8+ T Cells, Plays An Essential Role In Killing Myeloma Cells (2010) (1)
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. (2023) (1)
Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment (2018) (1)
Prostate Cancer Volume (1997) (1)
Acquired Nonfamilial Melanoma: An Inappropriate Conclusion-Reply (1987) (1)
Abstract B179: Targeted next generation sequencing for somatic mutations in human cancer. (2013) (1)
Immune deserts: Correlation of low CD8 gene expression with non-response to checkpoint inhibition. (2018) (1)
Treatment of cerebral metastases. (1982) (1)
NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker study. (2014) (0)
Abstract 3158: Ex vivo expansion and activation of human lymphocytes with a selective activator of effector cells (2015) (0)
Contents Vol. 96, 2019 (2019) (0)
Rapid Communication Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients i (2005) (0)
Abstract 1626: Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification (2017) (0)
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC (2022) (0)
Prognostic significance of isolated immunohistochemical positive cells and metastatic tumor burden in sentinel lymph nodes from melanoma patients (2016) (0)
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01) (2014) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
Chemo-hormonal therapy for biochemical progression of prostate cancer. (2006) (0)
Abstract 1818: Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics (2023) (0)
Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques (1996) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
MP29-11 TRANSCRIPTION FACTOR PROFILE OF MONOCYTES AND DENDRITIC CELLS (DC) IN RENAL CELL CARCINOMA (RCC) PATIENTS MAY DETERMINE RESPONSE TO IMMUNOTHERAPY (2014) (0)
CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma (2014) (0)
Serum cytokine profile in metastatic renal cell carcinoma (RCC) patients undergoing immunotherapy (2008) (0)
Development and Validation of a Melanoma Risk Score Based on PooledData from 16 Case – Control Studies (2015) (0)
Abstract 799: Clinical correlation of variable expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: Analysis of a tissue microarray using immunostaining scores (2010) (0)
Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC). (2017) (0)
Outcome predictors in patients receiving high-dose interleukin-2 therapy for the treatment of metastatic melanoma and renal cell carcinoma. (2014) (0)
Abstract 1983: Cancer exosomes immunosuppressive activity in the absence of contaminating soluble factors is multifactorial (2019) (0)
347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial (2020) (0)
Endocrine Toxicities of Immunotherapy (2020) (0)
A R Cel Imm (2010) (0)
Large Scale Expansion of Activated T Cells: Defining Procedures and Cryopreservation Methods for Clinical Use as Adoptive Cellular Therapy Post-Transplant. (2006) (0)
Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy (2020) (0)
Overcoming the logistics of immune monitoring of cancer patients during clinical trials (2012) (0)
Abstract 4057: Measurement of myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), CD8+and CD4+T-cells, and cytokines/chemokines in patients with metastatic melanoma treated with pembrolizumab and propranolol (2019) (0)
Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts). (2018) (0)
Myeloid derived suppressor cells (MDSC) correlate with inflammatory biomarkers in metastatic urothelial carcinoma (mUC) (2017) (0)
Induction of T cell precursors in advanced melanoma treated with autologous tumor lysate loaded dendritic cells (2004) (0)
Table of Contents (2020) (0)
Novel Combinatorial Immunotherapy for Melanoma (2015) (0)
Two New Appointments Announced at Norris Cotton Cancer Center and Geisel Medical School (2013) (0)
Suppressor (CD8+/CD28-) T cells are increased in cancer patients and inhibit helper T-cell proliferation. (2004) (0)
Cardivascular Toxicities of Immunotherapy (2020) (0)
Induction of T cell precursors in advanced melanoma treated with autologous tumor lysate loaded dendritic cells. (2004) (0)
Immune Mobilization with IL-2 and Growth Factors: Differential in Vivo Effects of the NKG2D Receptor on CD8+ and CD56+ Effector Cells (2008) (0)
Abstract A82: Immune checkpoint protein VISTA controls antitumor immunity via regulating Toll-like receptor signaling and myeloid cells-mediated inflammation (2020) (0)
Abstract 3682: Expression levels of genes in primary melanoma associated with clinically meaningful characteristics (2018) (0)
120 SCINTIGRAPHY OF METASTATIC MELANOMA UTILIZING IN-111-DTPA LABELED ANTI-p97 MONOCLONAL ANTIBODY (MoAb) 96.5 (1986) (0)
Pathway Alterations in Stage II/III Primary Melanoma. (2023) (0)
Extracellular proteases in renal cell carcinoma. (2011) (0)
Aberrant p53 expression is associated with early disease recurrence in patients undergoing radical prostatectomy (1997) (0)
Contents Vol. 97, 2019 (2019) (0)
NCCN: Continuing Education (2019) (0)
Abstract 3679: PD-L1 driven excluded phenotype in melanoma (2018) (0)
Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. (2011) (0)
Human genes differ by their UV sensitivity estimated through analysis of UV‐induced silent mutations in melanoma (2020) (0)
Validation of a prognostic 53-immune-gene panel in stage II/III melanoma. (2018) (0)
Letter to the editor (2014) (0)
Using the tumor microenvironment to identify predictors of immunotoxicity to checkpoint inhibitors. (2021) (0)
Abstract 1625: NGS reveals specimen characteristics have minimal impact on immune gene expression signature (2017) (0)
Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB). (2018) (0)
Abstract 4526: Predicting response: PD-L1 biomarker testing by IHC and RNA-seq (2018) (0)
Cancer Therapy : Clinical Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin ( Interleukin 2 ) and IFN-α 2 a Therapy in Metastatic Renal Cell Carcinoma Patients (2009) (0)
List of Contributors (2019) (0)
Abstract CT568: β-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma (2022) (0)
Genomic diversity in established melanoma cell lines and human melanoma tumors. (2016) (0)
Contents Vol. 78, 2010 (2010) (0)
321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer (2020) (0)
Analytical validation of an immune response assay for classifying solid tumors. (2017) (0)
Contents Vol. 95, 2018 (2018) (0)
Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy: A Pilot Study (2023) (0)
Evaluation of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and pathologic response in urothelial carcinoma (UC). (2016) (0)
Abstract 620: Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient (2017) (0)
Abstract 5070: Chemokine expression signatures in infiltrated vs non-infiltrated tumors (2018) (0)
Circulating T-Cell Biomarkers to Predict Response to Immune Checkpoint Inhibitors (2018) (0)
Correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC). (2016) (0)
A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma. (2015) (0)
Abstract 1044: Frequency of circulating CX3CR1+ CD8+ T cells to predict response to immune checkpoint inhibitor therapy (2020) (0)
Safety and preliminary activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma (mRCC): A cytokine working group study. (2017) (0)
Therapeutic Strategies for the Treatment of Metastatic Melanoma—What is New is Old (2005) (0)
Phase I II M ulticenter R andomized T rial o f t he D artmouth Regimen V ersus D acarbazine i n P atients With M etastatic M elanoma (1999) (0)
151: Immunotherapy immediately following transplantation for multiple myeloma: Early recovery of aggressive cytotoxic cells and improved immune resurgence (2007) (0)
Subject Index Vol. 78, 2010 (2010) (0)
Characterization of nTreg in patients with metastatic renal cell carcinoma (RCC) undergoing DC-vaccination and cytokine therapy (2008) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
Carcinoma of unknown primary: a 20 year retrospective analysis. (1985) (0)
94: Immune mobilization of autologous peripheral blood progenitor cells:IL-2 with GM-CSF and G-CSF results in effective mobilization without delay in engraftment (2007) (0)
Developing a RationalTumorVaccineTherapy for Renal Cell Carcinoma: ImmuneYin andYang (2007) (0)
Personalized Medicine—Some Things To Consider (2013) (0)
2022-RA-588-ESGO Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients with advanced solid tumours: ARTISTRY-1 (2022) (0)
Urinary Excretion of Interferon, Albumin, and /?2-Microglobulin during Interferon Treatment1 (2006) (0)
The development and characterization of a natural killer cell-resistant human renal cell carcinoma cell line. (1992) (0)
Future-proofing cell therapy manufacturing capability: lessons from the NCI (2021) (0)
503: Intranodal Tumor Lysate-Loaded Dendritic Cell Vaccine, Combined with Interleukin-2 and Interferon-A, In Patients with Metastatic Renal Cell Carcinoma - Exciting Clinical Results and Immunologic Data (2007) (0)
1796 PREDICTION FOR AND MECHANISM OF RESPONSE TO DENDRITIC CELL (DC)-BASED IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA (RCC)– GENE EXPRESSION PROFILING OF PERIPHERAL BLOOD LYMPHOCYTES (PBL) (2010) (0)
Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growth (2023) (0)
Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma (2017) (0)
Methylation of nonessential genes in cutaneous melanoma – Rule Out hypothesis (2023) (0)
Front & Back Matter (2012) (0)
Abstract 5087: Human melanoma exosomes induce metabolic reprogramming in human adult dermal fibroblasts (2018) (0)
Neurological Toxicities of Immunotherapy (2020) (0)
Parameters of interferon action. Natural killer (NK) activation during a phase II trial (1982) (0)
440 GENOMIC PROFILING OF MONOCYTES IN PATIENT WITH METASTATIC RENAL CELL CARCINOMA (RCC) TREATED WITH IMMUNOTHERAPY (2012) (0)
2178 Drug development core facilitates institutional collaboration and translational science innovation (2018) (0)
786: T Regulatory (TR) and T Suppressor (TS) Cells in the Peripheral Blood of Patients with Renal Cell Carcinoma (2004) (0)
Gastrointestinal Toxicities of Immunotherapy (2020) (0)
1799 GENE EXPRESSION PROFILES OF LYMPHOCYTES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (RCC) TREATED WITH DENDRITIC CELL (DC)-BASED IMMUNOTHERAPY (2010) (0)
Emerging role of RNA binding protein UNR/CSDE1 in melanoma. (2017) (0)
23 EFFICACY AND SAFETY OF VEDOLIZUMAB AND INFLIXIMAB TREATMENT FOR IMMUNE-MEDIATED DIARRHEA AND COLITIS IN CANCER PATIENTS: A MULTI-CENTER STUDY (2021) (0)
Abstract 2400: Treatment of colorectal cancer patients after resection of metastases with a tumor lysate pulsed dendritic cell vaccine: association between immune response and recurrence free survival (2010) (0)
PROSTATE CANCER VOLUME; AUTHORS' REPLY (1997) (0)
Pegylated I nterferon A lfa-2b T reatment f or P atients W ith Solid T umors: A P hase I /II S tudy (2002) (0)
MP47-16 PRETREATMENT PERIPHERAL BLOOD MONOCYTE SUBSET SIGNATURE IN STAGE IV RENAL CELL CARCINOMA PATIENTS PREDICTS OUTCOME TO DENDRITIC CELL VACCINATION (2015) (0)
DVSPLASTIC NEVI AND MULTIPLE PRIMARY MELANOMA Cases and Controls (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Marc S. Ernstoff?

Marc S. Ernstoff is affiliated with the following schools:

McGill University
University of Louisville
University of Michigan
Stanford University
Massachusetts Institute of Technology
University of Iowa
Massachusetts General Hospital
King's College London

Marc S. Ernstoff's Academic­Influence.com Rankings

Why Is Marc S. Ernstoff Influential?

Marc S. Ernstoff's Published Works

Published Works

What Schools Are Affiliated With Marc S. Ernstoff?

Marc S. Ernstoff's AcademicInfluence.com Rankings